Suppr超能文献

评估冷冻消融治疗转移性肺肿瘤患者的安全性和疗效:ECLIPSE 试验——1 年的中期分析。

Evaluating Cryoablation of Metastatic Lung Tumors in Patients--Safety and Efficacy: The ECLIPSE Trial--Interim Analysis at 1 Year.

机构信息

*Department of Radiology, Gustave Roussy-Cancer Campus, Villejuif, France; †Université Paris-Sud XI, UFR Médecine Le Kremlin-Bicêtre, Le Kremlin Bicêtre, France; ‡Department of Radiology, Mayo Clinic and Mayo Medical School, Rochester, Minnesota; §Department of Radiological Sciences, Ronald Reagan UCLA Medical Center, Los Angeles, California; and ‖Department of Radiology, Karmanos Cancer Institute, Detroit, Michigan.

出版信息

J Thorac Oncol. 2015 Oct;10(10):1468-74. doi: 10.1097/JTO.0000000000000632.

Abstract

INTRODUCTION

To assess the feasibility, safety and local tumor control of cryoablation for treatment of pulmonary metastases.

MATERIALS AND METHODS

This Health Insurance Portability and Accountability Act (HIPAA) compliant, IRB-approved, multicenter, prospective, single arm study included 40 patients with 60 lung metastases treated during 48 cryoablation sessions, with currently a minimum of 12 months of follow-up. Patients were enrolled according to the following key inclusion criteria: 1 to 5 metastases from extrapulmonary cancers, with a maximal diameter of 3.5 cm. Local tumor control, disease-specific and overall survival rates were estimated using the Kaplan-Meier method. Complications and changes in physical function and quality of life were also evaluated using Karnofsky performance scale, Eastern Cooperative Oncology Group performance status classification, and Short Form-12 health survey.

RESULTS

Patients were 62.6 ± 13.3 years old (26-83). The most common primary cancers were colon (40%), kidney (23%), and sarcomas (8%). Mean size of metastases was 1.4 ± 0.7 cm (0.3-3.4), and metastases were bilateral in 20% of patients. Cryoablation was performed under general anesthesia (67%) or conscious sedation (33%). Local tumor control rates were 56 of 58 (96.6%) and 49 of 52 (94.2%) at 6 and 12 months, respectively. Patient's quality of life was unchanged over the follow-up period. One-year overall survival rate was 97.5%. The rate of pneumothorax requiring chest tube insertion was 18.8%. There were three Common Terminology Criteria for Adverse Events grade 3 procedural complications during the immediate follow-up period (pneumothorax requiring pleurodesis, noncardiac chest pain, and thrombosis of an arteriovenous fistula), with no grade 4 or 5 complications.

CONCLUSION

Cryoablation is a safe and effective treatment for pulmonary metastases with preserved quality of life following intervention.

摘要

介绍

评估冷冻消融治疗肺转移瘤的可行性、安全性和局部肿瘤控制情况。

材料和方法

本研究符合《健康保险流通与责任法案》(HIPAA)和机构审查委员会(IRB)的规定,为一项多中心、前瞻性、单臂研究,共纳入 40 例患者的 60 个肺转移灶,在 48 次冷冻消融过程中进行治疗,目前的随访时间至少为 12 个月。根据以下主要纳入标准招募患者:1 至 5 个来自肺外癌症的转移灶,最大直径为 3.5cm。采用 Kaplan-Meier 法估计局部肿瘤控制率、疾病特异性生存率和总生存率。还使用 Karnofsky 表现量表、东部合作肿瘤学组表现状态分类和简短形式 12 项健康调查评估并发症以及身体功能和生活质量的变化。

结果

患者的年龄为 62.6±13.3 岁(26-83 岁)。最常见的原发癌为结肠癌(40%)、肾癌(23%)和肉瘤(8%)。转移灶的平均大小为 1.4±0.7cm(0.3-3.4cm),20%的患者为双侧转移灶。冷冻消融在全身麻醉(67%)或清醒镇静(33%)下进行。6 个月和 12 个月时,58 个目标病灶中有 56 个(96.6%)和 52 个(94.2%)达到局部肿瘤控制。患者的生活质量在随访期间保持不变。1 年总生存率为 97.5%。需要插入胸腔引流管的气胸发生率为 18.8%。在即时随访期间有 3 例常见不良事件术语标准 3 级手术并发症(需要胸膜固定术的气胸、非心源性胸痛和动静脉瘘血栓形成),无 4 级或 5 级并发症。

结论

冷冻消融治疗肺转移瘤是一种安全有效的方法,可保留干预后的生活质量。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验